Darrell J. Irvine

This study shows that mRNA vaccines can prime and mature ultrarare HIV bnAb precursor B cells in NHPs, with improved affinity using a modified immunogen.

The paper shows that early clonal dominance in B-cell precursors after vaccination predicts the breadth of HIV-neutralizing antibodies in rhesus macaques.

This study identifies an effector-primed TCF1+ CD8+ T cell state linked to delayed SHIV acquisition and reduced viral load in vaccinated non-human primates.

This study tracks germinal center responses in rhesus macaques over a year, showing prolonged GCs with declining SHM and ongoing plasma cell production.

This study develops ALD-coated microparticles for vaccines that enable controlled antigen release and enhance immune responses against HIV.

Epitope-focused S2 stem-helix nanoparticle immunogens elicit protective broadly neutralizing antibodies against diverse betacoronaviruses in non-human primates, establishing a framework for pan-betacoronavirus vaccines.

This study shows that a germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques by priming V2-apex bnAb B cell precursors.

DNA origami particles displaying eOD-GT8 with a synthetic T helper epitope gave antigen-focused germinal centers and expanded VRC01-class precursors in humanized mice after one immunization.

This study vaccinates nonhuman primates with SARS-CoV-2 and MERS-CoV spike proteins to elicit cross-reactive antibodies that neutralize both sarbecoviruses and merbecoviruses.

The paper shows that anionic polypeptide coatings on nanoparticles bind to cancer-associated amino acid transporters, enabling targeted drug delivery through electrostatic interactions and transporter clustering.

This study develops IL-12-loaded nanoparticles that enhance immunotherapy for metastatic ovarian cancer by promoting T cell accumulation and sensitizing tumors to checkpoint inhibitors.

This study shows a novel two-step mechanism for inducing broadly neutralizing HIV antibodies in macaques using a modified SHIV, informing vaccine design.

This study shows that HIV Env trimers coupled to liposomes induce cross-neutralizing antibodies in NHPs that mimic human bNAbs targeting the Env trimer apex.

This study shows that PPARγ downregulation in colonic CD8+ T cells of people with HIV on ART leads to epithelial barrier disruption by promoting lipid uptake and apoptosis.

This paper introduces WIN332, an engineered immunogen that elicits N332-glycan-independent V3-glycan antibodies in nonhuman primates after a single immunization.

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.

This study shows that targeting the conserved HIV fusion peptide with modified Env immunogens in rhesus macaques can focus immune responses on neutralizing epitopes.

Membrane-bound BG505 MD39.3 Env trimer delivered as mRNA-LNP reduced base-directed antibody responses in rabbits and macaques and elicited neutralizing antibodies, with memory B cell responses documented in macaques.

This study shows that CD45 sequestration lowers T cell activation thresholds and enhances anti-tumor immunity when combined with IL-12 therapy in mouse models.

This study shows that combining slow antigen delivery and follicle-targeting adjuvants enhances germinal center B cell diversity and clonal expansion in mice.

This study shows that a single immunization with a germline-targeting trimer can induce broad HIV-1 neutralizing antibodies in a rhesus macaque bnAb mouse model.

This paper designs a drug-regulated gene expression system using self-amplifying RNA with TMP-responsive degradation domains, showing enhanced immune responses in mice.

This paper improves mRNA vaccine efficacy by creating an inflammatory immune niche via injectable hydrogel depots that recruit immune cells and enhance humoral responses.

The paper investigates how vaccine antigen delivery and adjuvant selection affect the priming of rare HIV broadly neutralizing antibody-precursor B cells in non-human primates, finding that specific dosing and adjuvant combinations enhance their detection in germinal centers.

This study shows that co-delivering siRNA targeting IFNAR1 with RNA vaccines enhances antigen expression, immune cell infiltration, and antibody and T cell responses.

This study evaluates the dose-dependent effects of the SMNP adjuvant on HIV Env-specific immune responses in non-human primates, showing increased memory T and B cell responses and neutralizing antibodies at higher doses.

This study visualizes lipid nanoparticle trafficking in non-human primates using PET imaging, showing distribution to muscle and draining lymph nodes with uptake by antigen-presenting cells.

This study compares the immune response in non-human primates between alum and SMNP adjuvants, finding SMNP induces stronger humoral responses and enhanced lymph node activation.

This study shows that a two-dose extended priming vaccine regimen enhances humoral immune responses by synchronizing antigen delivery with germinal center dynamics.

This study develops glycan-costumed virus-like particles that activate dendritic cells and induce type 1 anti-tumor immunity in a murine model.